Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis.
The classic model of tumor suppression implies that malignant transformation requires full "two-hit" inactivation of a tumor-suppressor gene. However, more recent work in mice has led to the proposal of a "continuum" model that involves more fluid concepts such as gene dosage-sen...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
American Association for Cancer Research Inc.
2014
|
| _version_ | 1797069908102610944 |
|---|---|
| author | Couvé, S Ladroue, C Laine, E Mahtouk, K Guégan, J Gad, S Le Jeune, H Le Gentil, M Nuel, G Kim, W Lecomte, B Pagès, J Collin, C Lasne, F Benusiglio, P Bressac-de Paillerets, B Feunteun, J Lazar, V Gimenez-Roqueplo, A Mazure, N Dessen, P Tchertanov, L Mole, D Kaelin, W Ratcliffe, P |
| author_facet | Couvé, S Ladroue, C Laine, E Mahtouk, K Guégan, J Gad, S Le Jeune, H Le Gentil, M Nuel, G Kim, W Lecomte, B Pagès, J Collin, C Lasne, F Benusiglio, P Bressac-de Paillerets, B Feunteun, J Lazar, V Gimenez-Roqueplo, A Mazure, N Dessen, P Tchertanov, L Mole, D Kaelin, W Ratcliffe, P |
| author_sort | Couvé, S |
| collection | OXFORD |
| description | The classic model of tumor suppression implies that malignant transformation requires full "two-hit" inactivation of a tumor-suppressor gene. However, more recent work in mice has led to the proposal of a "continuum" model that involves more fluid concepts such as gene dosage-sensitivity and tissue specificity. Mutations in the tumor-suppressor gene von Hippel-Lindau (VHL) are associated with a complex spectrum of conditions. Homozygotes or compound heterozygotes for the R200W germline mutation in VHL have Chuvash polycythemia, whereas heterozygous carriers are free of disease. Individuals with classic, heterozygous VHL mutations have VHL disease and are at high risk of multiple tumors (e.g., CNS hemangioblastomas, pheochromocytoma, and renal cell carcinoma). We report here an atypical family bearing two VHL gene mutations in cis (R200W and R161Q), together with phenotypic analysis, structural modeling, functional, and transcriptomic studies of these mutants in comparison with classical mutants involved in the different VHL phenotypes. We demonstrate that the complex pattern of disease manifestations observed in VHL syndrome is perfectly correlated with a gradient of VHL protein (pVHL) dysfunction in hypoxia signaling pathways. Thus, by studying naturally occurring familial mutations, our work validates in humans the "continuum" model of tumor suppression. |
| first_indexed | 2024-03-06T22:31:20Z |
| format | Journal article |
| id | oxford-uuid:5861e924-92d1-4e74-9ea2-9ecdeb0fff42 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T22:31:20Z |
| publishDate | 2014 |
| publisher | American Association for Cancer Research Inc. |
| record_format | dspace |
| spelling | oxford-uuid:5861e924-92d1-4e74-9ea2-9ecdeb0fff422022-03-26T17:03:01ZGenetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:5861e924-92d1-4e74-9ea2-9ecdeb0fff42EnglishSymplectic Elements at OxfordAmerican Association for Cancer Research Inc.2014Couvé, SLadroue, CLaine, EMahtouk, KGuégan, JGad, SLe Jeune, HLe Gentil, MNuel, GKim, WLecomte, BPagès, JCollin, CLasne, FBenusiglio, PBressac-de Paillerets, BFeunteun, JLazar, VGimenez-Roqueplo, AMazure, NDessen, PTchertanov, LMole, DKaelin, WRatcliffe, PThe classic model of tumor suppression implies that malignant transformation requires full "two-hit" inactivation of a tumor-suppressor gene. However, more recent work in mice has led to the proposal of a "continuum" model that involves more fluid concepts such as gene dosage-sensitivity and tissue specificity. Mutations in the tumor-suppressor gene von Hippel-Lindau (VHL) are associated with a complex spectrum of conditions. Homozygotes or compound heterozygotes for the R200W germline mutation in VHL have Chuvash polycythemia, whereas heterozygous carriers are free of disease. Individuals with classic, heterozygous VHL mutations have VHL disease and are at high risk of multiple tumors (e.g., CNS hemangioblastomas, pheochromocytoma, and renal cell carcinoma). We report here an atypical family bearing two VHL gene mutations in cis (R200W and R161Q), together with phenotypic analysis, structural modeling, functional, and transcriptomic studies of these mutants in comparison with classical mutants involved in the different VHL phenotypes. We demonstrate that the complex pattern of disease manifestations observed in VHL syndrome is perfectly correlated with a gradient of VHL protein (pVHL) dysfunction in hypoxia signaling pathways. Thus, by studying naturally occurring familial mutations, our work validates in humans the "continuum" model of tumor suppression. |
| spellingShingle | Couvé, S Ladroue, C Laine, E Mahtouk, K Guégan, J Gad, S Le Jeune, H Le Gentil, M Nuel, G Kim, W Lecomte, B Pagès, J Collin, C Lasne, F Benusiglio, P Bressac-de Paillerets, B Feunteun, J Lazar, V Gimenez-Roqueplo, A Mazure, N Dessen, P Tchertanov, L Mole, D Kaelin, W Ratcliffe, P Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. |
| title | Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. |
| title_full | Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. |
| title_fullStr | Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. |
| title_full_unstemmed | Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. |
| title_short | Genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis. |
| title_sort | genetic evidence of a precisely tuned dysregulation in the hypoxia signaling pathway during oncogenesis |
| work_keys_str_mv | AT couves geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT ladrouec geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT lainee geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT mahtoukk geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT gueganj geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT gads geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT lejeuneh geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT legentilm geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT nuelg geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT kimw geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT lecomteb geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT pagesj geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT collinc geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT lasnef geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT benusigliop geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT bressacdepailleretsb geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT feunteunj geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT lazarv geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT gimenezroqueploa geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT mazuren geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT dessenp geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT tchertanovl geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT moled geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT kaelinw geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis AT ratcliffep geneticevidenceofapreciselytuneddysregulationinthehypoxiasignalingpathwayduringoncogenesis |